Director Anna U Loengard buys 26,500 shares at $2.59–$2.60 for $68,755; holding surges to 29,610 shares (+852.1%)
Director Loengard executed 2 separate open-market purchases totaling 26,500 shares for $68,755.00 on 2025-08-13, elevating her stake from 3,110 to 29,610 shares—a gain of +852.1% in absolute holdings. Her prior 5 trades at CLOV were all buys, and all showed positive 90-day returns (ranging +43.8% to +186.0%), indicating she has demonstrated consistent timing at this ticker. Against this pattern, the current macro backdrop is notably challenging: the stock trades at -46.7% from its 52-week high, down -27.6% over 90 days, and the company reported negative net income of $-10.6M alongside -32.6% annual revenue decline. The timing signal must be weighed against the company's deteriorating fundamentals—her historical success at CLOV does not guarantee predictive power in a materially changed business environment.